Citigroup boosted its price objective on BioAge, and Needham & Company began coverage of the company.
3 reports, 1 independent
Updated Sep 7
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup boosted its price objective on BioAge, and Needham & Company began coverage of the company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
BioAge
company in Lamezia Terme, Italy
Nothing else this week.
-
Needham & Company
American independent investment bank and asset management firm
Related events
- Citigroup reaffirmed a market outperform rating for HealthEquity.
- Citigroup reiterated a market perform rating for Inhibrx Biosciences.
- Citigroup reiterated a positive rating on BioPharma on October 7, 2026.
- Citigroup upped its price objective and gave a 'buy' rating, while Royal Bank of Canada reissued an 'outperform' rating for Abbott Laboratories.
- Citigroup set a $51.00 target price for GFL Environmental.